<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23030" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Genetics, Human Major Histocompatibility Complex (MHC)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tumer</surname>
            <given-names>Gizem</given-names>
          </name>
          <aff>Indiana University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Simpson</surname>
            <given-names>Brittany</given-names>
          </name>
          <aff>Cincinnati Children's Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Roberts</surname>
            <given-names>Tiffany K.</given-names>
          </name>
          <aff>University of Louisville</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gizem Tumer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brittany Simpson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tiffany Roberts declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23030.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The HLA (human leukocyte antigens) complex is located on the short arm of chromosome 6.<xref ref-type="bibr" rid="article-23030.r1">[1]</xref><xref ref-type="bibr" rid="article-23030.r2">[2]</xref><xref ref-type="bibr" rid="article-23030.r3">[3]</xref> The HLA genes&#x000a0;follow the principles of Mendelian genetics and the encoded antigens are co-dominantly expressed on the cell surface. In the absence of a recombination event, HLA genes are normally inherited <italic toggle="yes">en bloc </italic>from each parent due to their close proximity&#x000a0;resulting in their close physical linkage. The HLA haplotype&#x000a0;is a combination of linked HLA genes (HLA-A, -B,-C,-DR, -DQ,-DP) transmitted on a single parental chromosome.<xref ref-type="bibr" rid="article-23030.r2">[2]</xref> HLA antigens are expressed on the surface of many cells and play a major role in self-recognition, evoking the immune response to an antigenic stimulus, and to the orchestration of cellular and humoral immunity.<xref ref-type="bibr" rid="article-23030.r1">[1]</xref><bold>&#x000a0;</bold> HLA complex is known to be highly polygenic as it is composed of many genes, which can divide broadly into three categories: Class I, Class II, and Class III.<xref ref-type="bibr" rid="article-23030.r2">[2]</xref> Polymorphism is another feature of the HLA molecule. Polymorphism allows the presence&#x000a0;of&#x000a0;multiple variations of antigens or alleles. The HLA class I and class II antigens have the most highly polymorphic structural genes found in humans, which allows amino acids in any given HLA molecule to vary slightly from one person to the next. This variation generates distinct HLA types and also causes allograft rejection when tissues are transplanted.<xref ref-type="bibr" rid="article-23030.r4">[4]</xref></p>
      </sec>
      <sec id="article-23030.s2" sec-type="Development">
        <title>Development</title>
        <p>The foundations of the HLA complex were laid down in 1958 by three scientists: Jean Dausett, Jon van Rood, and Rose Payne.&#x000a0;They described the presence of alloantigens on leukocytes in human sera obtained from multiparous women or patients who had received multiple transfusions in three separate papers.<xref ref-type="bibr" rid="article-23030.r5">[5]</xref><xref ref-type="bibr" rid="article-23030.r6">[6]</xref><xref ref-type="bibr" rid="article-23030.r7">[7]</xref> Among the three, Jean Dausett was given credit for the discovery of the first HLA antigen, and in 1980 he received the Nobel prize. Discovery of the HLA is the first milestone of the field of immunohistocompatibility. However, the impact of immunohistocompatibility testing in transplantation was established in 1969. Patel and Terasaki demonstrated in kidney transplantation recipient and donors pairs that there is a&#x000a0; strong correlation between a positive lymphocyte crossmatch and a hyperacute rejection as a common outcome.<xref ref-type="bibr" rid="article-23030.r8">[8]</xref> This compelling data resulted in a mandatory prospective crossmatch before kidney transplantation to identify the antibodies reacting with donor lymphocytes that have the potential to cause a graft loss.</p>
      </sec>
      <sec id="article-23030.s3" sec-type="Biochemical">
        <title>Biochemical</title>
        <p>Structure</p>
        <p>Class I and Class II molecules differ structurally. HLA Class I molecules are comprised of a polymorphic alpha chain, which is encoded by the Class I genes, and the B2 microglobulin chain, which is encoded by a gene on chromosome 15. The alpha chain is also known as the heavy chain and also has three domains: alpha 1, 2 and 3. The alpha1 and alpha2 domains contain the majority of polymorphic regions conferring HLA antigen specificity. HLA Class II molecules have one alpha chain and a beta chain.<xref ref-type="bibr" rid="article-23030.r3">[3]</xref><xref ref-type="bibr" rid="article-23030.r9">[9]</xref> Class II region contains DR, DQ, and DP. Each class II molecule has two genes, A and B encoding the alpha and beta chains.<xref ref-type="bibr" rid="article-23030.r9">[9]</xref><xref ref-type="bibr" rid="article-23030.r10">[10]</xref></p>
      </sec>
      <sec id="article-23030.s4" sec-type="Function">
        <title>Function</title>
        <p>The MHC genes that act as transplantation antigens are the classical HLA genes. The classical HLA class I genes (HLA-A, -B and -C) express on most of the somatic cells in the body. Classical HLA Class II genes (HLA-DR,-DQ, -DP) express on antigen presenting cells such as B- cells, activated T cells, dendritic cells, macrophages, and epithelial cells of thymic gland. If interferon is present<italic toggle="yes">, </italic>other types of cells can also express class II HLA molecules. The primary function is the distinction of self from non-self. Both class I and class II molecules present short peptides derived from pathogens to T cells to initiate the adaptive immune response. The HLA class I molecules display peptides that result from the degradation of cytosolic proteins to the cell surface where they can is recognizable by the CD8+T cells. HLA class II molecules present peptides that result from the degradation of <italic toggle="yes">endocytosed </italic>proteins to the cell surface where they are recognizable by the CD4+ T cells.<xref ref-type="bibr" rid="article-23030.r3">[3]</xref></p>
      </sec>
      <sec id="article-23030.s5" sec-type="Testing">
        <title>Testing</title>
        <p>HLA Typing:</p>
        <p>HLA typing is defined polymorphisms of class I and class II loci.<xref ref-type="bibr" rid="article-23030.r11">[11]</xref><bold>&#x000a0; </bold>Serology was the first HLA typing methodology. The microcytoxicity method&#x000a0;detects the presence of antigen by cytotoxic&#x000a0;cell death induced by activation of complement. In this in vitro assay, T or B lymphocytes are isolated from&#x000a0;an individual and are incubated with serum&#x000a0;containing HLA antibodies&#x000a0;of a&#x000a0;known HLA specificity obtained from multiparous women.<xref ref-type="bibr" rid="article-23030.r12">[12]</xref><xref ref-type="bibr" rid="article-23030.r13">[13]</xref> The enhancements of molecular methodology eliminate the necessity of HLA typing by using serum with anti-HLA antibodies of all HLA antigens. Although the polymorphisms of the HLA are widely distributed throughout the gene, the vast majority of the polymorphisms congregate within exons 2 and 3. In the modern day, molecular methods are used to identify the specific nucleotide sequence polymorphisms&#x000a0;distinctive of a&#x000a0;specific HLA&#x000a0;antigen. Subsequently, artificially synthesized&#x000a0;commercially available DNA probes or primers are used to detect HLA polymorphisms.<xref ref-type="bibr" rid="article-23030.r13">[13]</xref></p>
        <p>There are three different categories of&#x000a0;DNA based molecular HLA typing methods available. All of&#x000a0;these methods determine the HLA types based on polymorphisms identified by&#x000a0;polymerase chain reaction (PCR) technology which&#x000a0;uses a heat-stable DNA polymerase to amplify the target sequences of HLA genes rapidly.</p>
        <p>1- Sequence-specific primer (SSP) typing: This technique uses sequence-specific primer pairs that target and amplify a particular DNA sequence where PCR primers are designed to bind only to a specific HLA allele or allele groups.&#x000a0;Confirmation of the amplified alleles&#x000a0;is by the presence or absence of DNA amplification by a particular primer pair that are visualized by agarose gel electrophoresis<bold>.</bold><xref ref-type="bibr" rid="article-23030.r2">[2]</xref><xref ref-type="bibr" rid="article-23030.r13">[13]</xref> Sequence-specific primers&#x000a0;used in this method are directed to specific targets. Therefore the presence of the amplification will correspond to the presence of the designated allele(s). Commercially available primer pair sets can define a full HLA type of an individual (HLA-A, -B,-C, -DR, -DQ, and -DP). Deceased donor typing is the most common application of this method as it provides rapid results. This technique allows for low-resolution HLA typing&#x000a0;in the&#x000a0;DNA based typing nomenclature (A*01).<xref ref-type="bibr" rid="article-23030.r2">[2]</xref><xref ref-type="bibr" rid="article-23030.r14">[14]</xref> Disadvantage SSP typing is not suitable for testing a large number of samples.<xref ref-type="bibr" rid="article-23030.r2">[2]</xref></p>
        <p>2- Sequence-specific oligonucleotide probes (SSOP): This technique is frequently used in clinical histocompatibility laboratories. This method identifies HLA polymorphisms using oligonucleotide probes on a solid phase matrix (i.e., microbeads)&#x000a0;in broadly generated, exon and locus-specific PCR products.<xref ref-type="bibr" rid="article-23030.r13">[13]</xref> SSOP methodology provides low to high-level resolution (antigen level typing)&#x000a0;by DNA based typing results. This methodology is suitable for testing a large number of samples in batches.</p>
        <p>3- Sequence-based typing (SBT): This technique is performable on several different platforms. One is Sanger-based DNA sequencing, and the other&#x000a0;platforms have their basis in next-generation sequencing. The most common application of SBT typing is to identify<italic toggle="yes">&#x000a0;</italic>allelic level HLA typing for stem cell transplantation recipients and donors. An allele refers to a unique&#x000a0;nucleotide sequence for a gene. By DNA based typing nomenclature, allelic resolution utilizes all the digits in a current allele name. (A*01:01:01:01). This methodology allows for confirmation of new allelic sequences.<xref ref-type="bibr" rid="article-23030.r2">[2]</xref><xref ref-type="bibr" rid="article-23030.r13">[13]</xref><xref ref-type="bibr" rid="article-23030.r14">[14]</xref></p>
        <p>As HLA typing methods developed&#x000a0;and molecular HLA typing replaced serologic methodology,&#x000a0;HLA nomenclature has changed to reflect the complexity of the output of the advanced typing methodologies.<xref ref-type="bibr" rid="article-23030.r11">[11]</xref></p>
        <p>HLA Antibody Testing:</p>
        <p>Identification of HLA antibodies is important in a pre-transplant and post-transplant setting in solid organ transplantation. Currently, single antigen bead assays are the most common approach for HLA antibody identification. This test is a solid phase assay that utilizes microbeads coated with recombinant single HLA antigens. The analysis is performed on a specialized flow cytometry platform.<xref ref-type="bibr" rid="article-23030.r15">[15]</xref> Interpretation of this assay is highly complex and performed by specially trained laboratorians.</p>
        <p>Crossmatching:</p>
        <p>Flow cytometric crossmatch is an essential test to determine the compatibility between a donor and a recipient. It assay is frequently used prior to transplantation of solid organs.<xref ref-type="bibr" rid="article-23030.r2">[2]</xref></p>
      </sec>
      <sec id="article-23030.s6" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>HLA is an important barrier for hematopoietic stem cell (HPC) transplantation. Therefore, HLA matching and compatibility between the donor and the recipient is necessary for a successful HPC transplantation. HLA antigens also have a role in graft-versus-host disease (GVHD), a potentially serious complication of allogeneic stem cell transplantation. GVHD occurs when donor T cells react to host antigens on antigen-presenting cells (APCs) and attack host tissues, with sequential activation of donor T cells and monocytes/macrophages.<xref ref-type="bibr" rid="article-23030.r16">[16]</xref></p>
        <p>In solid organ transplantation, HLA antibodies play an important role, and HLA matching is not as important. With patient exposure to foreign HLA antigens due to pregnancy or blood transfusions or transplantation, they can make antibodies against epitopes of those foreign HLA molecules; this is called HLA alloimmunization. Presence of HLA antibodies against graft can cause antibody-mediated rejection and graft loss.<xref ref-type="bibr" rid="article-23030.r17">[17]</xref></p>
        <p>HLA alloimmunization can also cause platelet refractoriness. This condition creates difficulty in finding compatible platelet units, especially in transfusion-dependent HPC transplant patients. In platelet refractoriness HLA Class I antibodies especially antibodies against HLA-A and HLA-B play an important role.<xref ref-type="bibr" rid="article-23030.r18">[18]</xref> HLA antibodies also play a role in febrile nonhemolytic transfusion reactions and transfusion-related acute lung injury (TRALI).<xref ref-type="bibr" rid="article-23030.r19">[19]</xref></p>
      </sec>
      <sec id="article-23030.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23030&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23030">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23030/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23030">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23030.s8">
        <title>References</title>
        <ref id="article-23030.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sumitran-Holgersson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Beyond ABO and human histocompatibility antigen: other histocompatibility antigens with a role in transplantation.</article-title>
            <source>Curr Opin Organ Transplant</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>425</fpage>
            <page-range>425-9</page-range>
            <pub-id pub-id-type="pmid">18685340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howell</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The HLA system: immunobiology, HLA typing, antibody screening and crossmatching techniques.</article-title>
            <source>J Clin Pathol</source>
            <year>2010</year>
            <month>May</month>
            <volume>63</volume>
            <issue>5</issue>
            <fpage>387</fpage>
            <page-range>387-90</page-range>
            <pub-id pub-id-type="pmid">20418230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The HLA system. First of two parts.</article-title>
            <source>N Engl J Med</source>
            <year>2000</year>
            <month>Sep</month>
            <day>07</day>
            <volume>343</volume>
            <issue>10</issue>
            <fpage>702</fpage>
            <page-range>702-9</page-range>
            <pub-id pub-id-type="pmid">10974135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>C Aguiar</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Bitarello</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>C Brandt</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A genomic perspective on HLA evolution.</article-title>
            <source>Immunogenetics</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>70</volume>
            <issue>1</issue>
            <fpage>5</fpage>
            <page-range>5-27</page-range>
            <pub-id pub-id-type="pmid">28687858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DAUSSET</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Iso-leuko-antibodies].</article-title>
            <source>Acta Haematol</source>
            <year>1958</year>
            <season>Jul-Oct</season>
            <volume>20</volume>
            <issue>1-4</issue>
            <fpage>156</fpage>
            <page-range>156-66</page-range>
            <pub-id pub-id-type="pmid">13582558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>VAN ROOD</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>EERNISSE</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>VAN LEEUWEN</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Leucocyte antibodies in sera from pregnant women.</article-title>
            <source>Nature</source>
            <year>1958</year>
            <month>Jun</month>
            <day>21</day>
            <volume>181</volume>
            <issue>4625</issue>
            <fpage>1735</fpage>
            <page-range>1735-6</page-range>
            <pub-id pub-id-type="pmid">13566127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>PAYNE</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>ROLFS</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Fetomaternal leukocyte incompatibility.</article-title>
            <source>J Clin Invest</source>
            <year>1958</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>12</issue>
            <fpage>1756</fpage>
            <page-range>1756-63</page-range>
            <pub-id pub-id-type="pmid">13611043</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Terasaki</surname>
                <given-names>PI</given-names>
              </name>
            </person-group>
            <article-title>Significance of the positive crossmatch test in kidney transplantation.</article-title>
            <source>N Engl J Med</source>
            <year>1969</year>
            <month>Apr</month>
            <day>03</day>
            <volume>280</volume>
            <issue>14</issue>
            <fpage>735</fpage>
            <page-range>735-9</page-range>
            <pub-id pub-id-type="pmid">4886455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turner</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The human leucocyte antigen (HLA) system.</article-title>
            <source>Vox Sang</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>87 Suppl1</volume>
            <fpage>87</fpage>
            <page-range>87-90</page-range>
            <pub-id pub-id-type="pmid">15200613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shiina</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Inoko</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kulski</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>An update of the HLA genomic region, locus information and disease associations: 2004.</article-title>
            <source>Tissue Antigens</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>631</fpage>
            <page-range>631-49</page-range>
            <pub-id pub-id-type="pmid">15546336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tait</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>The ever-expanding list of HLA alleles: changing HLA nomenclature and its relevance to clinical transplantation.</article-title>
            <source>Transplant Rev (Orlando)</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">21030236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>TERASAKI</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>MCCLELLAND</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>MICRODROPLET ASSAY OF HUMAN SERUM CYTOTOXINS.</article-title>
            <source>Nature</source>
            <year>1964</year>
            <month>Dec</month>
            <day>05</day>
            <volume>204</volume>
            <fpage>998</fpage>
            <page-range>998-1000</page-range>
            <pub-id pub-id-type="pmid">14248725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Using HLA typing to support patients with cancer.</article-title>
            <source>Cancer Control</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-86</page-range>
            <pub-id pub-id-type="pmid">25504281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nunes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Heslop</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fernandez-Vina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taves</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wagenknecht</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Eisenbrey</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Poulton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wacker</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hurley</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Noreen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sacchi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Definitions of histocompatibility typing terms.</article-title>
            <source>Blood</source>
            <year>2011</year>
            <month>Dec</month>
            <day>01</day>
            <volume>118</volume>
            <issue>23</issue>
            <fpage>e180</fpage>
            <page-range>e180-3</page-range>
            <pub-id pub-id-type="pmid">22001389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roberts</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tumer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gebel</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Solid-phase assays for the detection of alloantibody against human leukocyte antigens: panacea or Pandora?</article-title>
            <source>Int J Immunogenet</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>362</fpage>
            <page-range>362-9</page-range>
            <pub-id pub-id-type="pmid">25066258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tie</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysis.</article-title>
            <source>Oncotarget</source>
            <year>2017</year>
            <month>Apr</month>
            <day>18</day>
            <volume>8</volume>
            <issue>16</issue>
            <fpage>27645</fpage>
            <page-range>27645-27660</page-range>
            <pub-id pub-id-type="pmid">28206973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loupy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lefaucheur</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Antibody-Mediated Rejection of Solid-Organ Allografts.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Sep</month>
            <day>20</day>
            <volume>379</volume>
            <issue>12</issue>
            <fpage>1150</fpage>
            <page-range>1150-1160</page-range>
            <pub-id pub-id-type="pmid">30231232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duquesnoy</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support?</article-title>
            <source>Transfusion</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>221</fpage>
            <page-range>221-7</page-range>
            <pub-id pub-id-type="pmid">18005328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23030.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tariket</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sut</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hamzeh-Cognasse</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Laradi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pozzetto</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Garraud</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Cognasse</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Transfusion-related acute lung injury: transfusion, platelets and biological response modifiers.</article-title>
            <source>Expert Rev Hematol</source>
            <year>2016</year>
            <month>May</month>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>497</fpage>
            <page-range>497-508</page-range>
            <pub-id pub-id-type="pmid">26855042</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
